secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K/A
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001193125-26-177317
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio pro forma continuing ops net income $114.9M after First Tracks spin-off
--------------------------------------------------------------------------------

- Pro forma continuing ops net income $114.9M for FY2025; basic EPS $3.99, diluted $3.07.
- Collaboration revenue $234.6M, operating income $217.9M after spin-off adjustments.
- AnaptysBio provided $100M cash distribution to First Tracks; expects $7M non-recurring costs within 12 months.
- Pro forma balance sheet as of Dec 31, 2025 shows negative stockholders' equity of $116.3M.
- First Tracks shares began trading on Nasdaq under ticker TRAX on April 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526177317/0001193125-26-177317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526177317/d104779d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-177317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer